The pathway to secondary prevention of Alzheimer's disease.

    Thumbnail
    Download
    Citations
    Altmetric
    Author
    McDade, E; Bednar, MM; Brashear, HR; Miller, DS; Maruff, P; Randolph, C; Ismail, Z; Carrillo, MC; Weber, CJ; Bain, LJ; ...
    Date
    2020
    Source Title
    Alzheimer's and Dementia: Translational Research and Clinical Interventions
    Publisher
    Wiley
    University of Melbourne Author/s
    Maruff, Paul
    Affiliation
    Anatomy and Neuroscience
    Metadata
    Show full item record
    Document Type
    Journal Article
    Citations
    McDade, E., Bednar, M. M., Brashear, H. R., Miller, D. S., Maruff, P., Randolph, C., Ismail, Z., Carrillo, M. C., Weber, C. J., Bain, L. J. & Hake, A. M. (2020). The pathway to secondary prevention of Alzheimer's disease.. Alzheimers Dement (N Y), 6 (1), pp.e12069-. https://doi.org/10.1002/trc2.12069.
    Access Status
    Open Access
    URI
    http://hdl.handle.net/11343/251576
    DOI
    10.1002/trc2.12069
    Open Access at PMC
    http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7453146
    Abstract
    Alzheimer's disease (AD) is a continuum consisting of a preclinical stage that occurs decades before symptoms appear. As researchers make advances in investigating the continuum, the importance of developing drugs for secondary prevention is garnering increased discussion. For efficacious drug development for secondary prevention it is important to define what are the earliest biological stages of AD. The Alzheimer's Association Research Roundtable convened November 27 to 28, 2018 to focus on pre-clinical AD. This review will address the biological approach to defining pre-clinical AD, detection, identification of at-risk individuals, and lessons learned from trials such as A4 and TOMMORROW.

    Export Reference in RIS Format     

    Publisher licence
    CC BY-NC-ND
    Collections